Combination of teriflunomide and interferon as follow-up therapy after fingolimod-associated PML

Neurol Neuroimmunol Neuroinflamm. 2020 Dec 3;8(1):e927. doi: 10.1212/NXI.0000000000000927. Print 2021 Jan.

Authors

Bettina Fischer-Barnicol¹, Johanna Oechtering², Jens Kuhle², Johannes Lorscheider², Ludwig Kappos², Tobias Derfuss²

Affiliations

¹ From the Neurologic Clinic and Policlinic, Departments of Medicine, Biomedicine and Clinical Research, University Hospital Basel, University of Basel, Switzerland. Bettina.fischer-barnicol@usb.ch.
² From the Neurologic Clinic and Policlinic, Departments of Medicine, Biomedicine and Clinical Research, University Hospital Basel, University of Basel, Switzerland.

No abstract available

Publication types

Case Reports

MeSH terms

Adjuvants, Immunologic / therapeutic use
Antiviral Agents / therapeutic use
Crotonates / therapeutic use*
Female
Fingolimod Hydrochloride / adverse effects
Humans
Hydroxybutyrates / therapeutic use*
Immune Reconstitution Inflammatory Syndrome / drug therapy
Immune Reconstitution Inflammatory Syndrome / etiology
Immunosuppressive Agents / adverse effects
Interferon beta-1a / therapeutic use*
Leukoencephalopathy, Progressive Multifocal / chemically induced*
Middle Aged
Multiple Sclerosis, Relapsing-Remitting / complications*
Multiple Sclerosis, Relapsing-Remitting / drug therapy*
Nitriles / therapeutic use*
Toluidines / therapeutic use*

Substances

Adjuvants, Immunologic
Antiviral Agents
Crotonates
Hydroxybutyrates
Immunosuppressive Agents
Nitriles
Toluidines
teriflunomide
Fingolimod Hydrochloride
Interferon beta-1a